Publications by authors named "Zi-Qing-Yun Yuan"
Background: Our study aims to explore the effect of genetics on the pharmacodynamics (PD) and pharmacokinetics (PK) of cinacalcet in healthy Chinese subjects; to investigate the effect of dietary factors on cinacalcet, and to evaluate the safety of cinacalcet under fasting and non-fasting conditions using a bioequivalence trial.
Methods: We investigated the relationship of cinacalcet PK with single nucleotide polymorphisms (SNPs) of CYP3A4, CYP1A2 and CYP2D6, and of cinacalcet PD with SNPs of calcium-sensitive receptors (CASR) and vitamin D receptors (VDR) in 65 healthy Chinese subjects recruited to participate in this study. Our study was a phase I, open-label, randomized, two-period, two-sequence crossover, a single-center clinical study designed under both fasting and non-fasting conditions to investigate the effect of dietary factors on cinacalcet.
This study investigated voriconazole (VRC) unbound plasma concentration and its relationship with adverse drug reactions (ADRs) in patients with malignant hematologic disease. Plasma samples were collected from patients or spiked . A time-saving rapid equilibrium dialysis assay was used for the separation of unbound and bound VRC, following a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) analysis method for drug concentration detection.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates how specific genetic variations (SNPs) and demographic factors affect the effectiveness of the blood pressure medication felodipine in healthy Chinese individuals.
- 24 participants were analyzed using advanced methods to determine the relationship between these genetic markers and blood pressure changes.
- Results indicate that individual responses to felodipine vary significantly, with certain SNPs particularly influencing systolic and diastolic blood pressure reductions.
Background: Platelet-derived Growth Factor Receptor (PDGFR) is a kind of Receptor Tyrosine Kinases (RTKs). PDGFR Tyrosine Kinase Inhibitors (TKIs) which are small molecule inhibitors targeting PDGFR prevent and block cell proliferation signal transduction pathways. Recently, there have been 11 TKIs (including imatinib, sunitinib, regorafenib, sorafenib, pazopanib, axitinib, dasatinib, nilotinib, lenvatinib, cabozantinib and ponatinib) targeting PDGFR approved by FDA for the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, renal cell carcinoma et al.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the safety, pharmacokinetics (how the drug moves in the body), and pharmacodynamics (how it affects the body) of S-(-)-pantoprazole sodium injections in healthy Chinese participants after various dosage administrations.
- Subjects received different single and multiple intravenous doses (20 mg, 40 mg, and 80 mg) of S-(-)-PPZ and were monitored for safety and effects on intragastric pH.
- Results showed that S-(-)-PPZ was safe with mild side effects, and the higher doses resulted in increased acid suppression compared to lower doses or the traditional pantoprazole, suggesting it may provide more effective acid inhibition.
Proton pump inhibitors (PPIs) are known as a class of pharmaceutical agents that target H/K-ATPase, which is located in gastric parietal cells. PPIs are widely used in the treatment of gastric acid-related diseases including peptic ulcer disease, erosive esophagitis and gastroesophageal reflux disease, and so on. These drugs present an excellent safety profile and have become one of the most commonly prescribed drugs in primary and specialty care.
View Article and Find Full Text PDFPurpose: This study was conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy subjects.
Methods: Dexlansoprazole (20-90 mg) or lansoprazole (30 mg) was administrated intravenously to healthy male and female volunteers. All the subjects were sampled for pharmacokinetic (PK) analysis and 64 of them were monitored for 24-h intragastric pH prior to and after administration in the pharmacodynamic (PD) study.